Description

Oltar (glimepiride) tablets 2 mg. №30

Ingredients

Active ingredient: Glimepiride 2 mg per tablet.

Dosage

Dosage: The usual starting dose is 1-2 mg once daily with breakfast or the first main meal. Dosage adjustments should be made based on blood glucose levels.

Indications

Indications: Oltar tablets are indicated for the treatment of type 2 diabetes mellitus when diet, exercise, and weight reduction alone are not adequate.

Contraindications

Contraindications: Do not use Oltar tablets in patients with a history of hypersensitivity to glimepiride or other sulfonylureas.

Directions

Directions: Swallow the tablet whole with a glass of water. Follow the dosage instructions provided by your healthcare provider.

Scientific Evidence

Glimepiride, the active ingredient in Oltar tablets, belongs to the sulfonylurea class of drugs. It works by stimulating the release of insulin from the pancreas, thereby lowering blood glucose levels. Studies have shown that glimepiride is effective in improving glycemic control in patients with type 2 diabetes.

Additional Information

It is important to monitor blood glucose levels regularly while taking Oltar tablets to ensure optimal control of diabetes. Adherence to a healthy diet and regular exercise regimen is essential for the best outcomes when using this medication.

Pharmacological Effects

Glimepiride acts by binding to specific receptors on pancreatic beta cells, leading to the closure of ATP-sensitive potassium channels. This closure results in depolarization of the cell membrane, opening of voltage-gated calcium channels, and subsequent insulin release. The pharmacological action of glimepiride helps to lower blood glucose levels in diabetic patients.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated the efficacy of glimepiride in improving HbA1c levels and overall glycemic control in patients with type 2 diabetes. Comparative studies have shown that glimepiride is as effective as other sulfonylureas in managing blood glucose levels. However, individual responses to different medications may vary, and healthcare providers should tailor treatment plans to each patient’s specific needs.

References:
1. Marre M, et al. Efficacy and safety of glimepiride in the treatment of type 2 diabetes: a comparative review. Diabetes Metab Res Rev. 2007;23(3):211-24.
2. Schernthaner G, et al. Efficacy and tolerability of glimepiride in the treatment of type 2 diabetes: a double-blind, randomized, placebo-controlled study. Diabetes Care. 2001;24(5):736-40.